Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

CURE Pharmaceutical to Participate in Panel Discussion on the Future of Clinical Research using Cannabis at The Cannabis Science Conference in Portland, OR

Posted on: 29 Aug 17

OXNARD, Calif., Aug. 29, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development company, will participate along with leading pioneers in clinical research in a “Future of Clinical Research Exposed” panel at this year’s Cannabis Science Conference in Portland, OR.

This groundbreaking panel will be moderated by CannaKids CEO, Tracy Ryan who CURE Pharmaceutical recently collaborated with along with the Technion Institute of Technology in Israel. CURE’s CEO Robert Davidson and Chief Business Officer, Jessica Rousset will be joined by Technion’s Dedi Meiri and CannaKids expert dosing professional and Mayo Clinic nurse Karen Roellich.

“We here at CURE believe that sharing our knowledge and understanding on ways the cannabis plant is being studied is something that is very important to the industry,” said Davidson. “We look forward to sharing here at the Cannabis Science Conference the current research underway at CURE as well as discussing the paths we see to get FDA approved drugs to market for those who can truly benefit from them.”

The Panel will take place at the Cannabis Science Conference at the Oregon Convention center in Portland, OR on Wednesday, August 30th at 1pm.

About CURE Pharmaceutical
CURE Pharmaceutical is a fully integrated specialty bioscience company improving drug efficacy, safety and the patient experience with proprietary drug dosage forms and delivery systems for a broad range of molecules. CURE has an industry leading full service cGMP manufacturing facility and is a preeminent developer and manufacturer of a patented and proprietary delivery system (CureFilm™), which includes the most advanced oral thin film on the market today. CURE has developed an array of products in cutting-edge delivery platforms and partners with leading pharmaceutical companies. CURE has positioned itself in the pharmaceutical cannabis sector with partnerships in the U.S., Canada, Israel and Germany, among other markets. The Company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.

For more information about CURE Pharmaceutical, please visit its website at  

Forward-looking statements
This press release contains forward-looking statements, which are subject to risks and uncertainties. All statements, other than statements of fact, including those statements with respect to the Company's business development, are forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.

CONTACT: Public Relations Contact Andrew Hard Chief Executive Officer CMW Media P. +1888 829-0070 www.cmwmedia.comGlobeNewswire

Last updated on: 30/08/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.